Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday

Neumora Therapeutics (NASDAQ:NMRA) will likely be announcing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:30 PM ET.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Monday, March 30th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). On average, analysts expect Neumora Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neumora Therapeutics Trading Down 0.6%

Neumora Therapeutics stock traded down $0.02 during trading on Monday, hitting $2.43. The company’s stock had a trading volume of 93,050 shares, compared to its average volume of 1,608,003. The stock has a market capitalization of $443.02 million, a price-to-earnings ratio of -1.67 and a beta of 3.02. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.87 and a current ratio of 5.87. The stock’s fifty day moving average is $2.58 and its 200 day moving average is $2.38. Neumora Therapeutics has a 1-year low of $0.61 and a 1-year high of $3.65.

Wall Street Analysts Forecast Growth

NMRA has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Tuesday, April 21st. Guggenheim restated a “buy” rating and set a $14.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 31st. Mizuho set a $6.00 price target on Neumora Therapeutics in a research note on Monday, January 5th. Needham & Company LLC restated a “buy” rating and set a $8.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 31st. Finally, Leerink Partners began coverage on Neumora Therapeutics in a research note on Monday, January 12th. They issued an “outperform” rating and a $8.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.67.

Insider Activity at Neumora Therapeutics

In related news, insider Paul L. Berns sold 9,819 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total transaction of $34,464.69. Following the completion of the sale, the insider owned 7,395,185 shares of the company’s stock, valued at $25,957,099.35. This represents a 0.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders sold 23,387 shares of company stock valued at $82,647. 26.94% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Neumora Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC acquired a new position in Neumora Therapeutics in the fourth quarter valued at approximately $27,000. Virtu Financial LLC bought a new stake in shares of Neumora Therapeutics in the 3rd quarter worth approximately $31,000. Fred Alger Management LLC bought a new stake in shares of Neumora Therapeutics in the 4th quarter worth approximately $40,000. Canada Pension Plan Investment Board bought a new stake in shares of Neumora Therapeutics in the 2nd quarter worth approximately $41,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Neumora Therapeutics in the 3rd quarter worth approximately $44,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.